Chimeric antibodies greatly improve the immunogenicity and limitations of non-parental antibodies applications. Chimeric technologies to engineered non-IgG antibodies are necessary. Taking IgA for instance, IgA Fc receptor, FcαRI, effectively triggers cytotoxicity. More information can be found at https://non-igg-ab.creative-bi....olabs.com/non-igg-th
Like
Comment
Share
